» Articles » PMID: 32098019

Communicating the Risk of Death from Novel Coronavirus Disease (COVID-19)

Overview
Journal J Clin Med
Specialty General Medicine
Date 2020 Feb 27
PMID 32098019
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

To understand the severity of infection for a given disease, it is common epidemiological practice to estimate the case fatality risk, defined as the risk of death among cases. However, there are three technical obstacles that should be addressed to appropriately measure this risk. First, division of the cumulative number of deaths by that of cases tends to underestimate the actual risk because deaths that will occur have not yet observed, and so the delay in time from illness onset to death must be addressed. Second, the observed dataset of reported cases represents only a proportion of all infected individuals and there can be a substantial number of asymptomatic and mildly infected individuals who are never diagnosed. Third, ascertainment bias and risk of death among all those infected would be smaller when estimated using shorter virus detection windows and less sensitive diagnostic laboratory tests. In the ongoing COVID-19 epidemic, health authorities must cope with the uncertainty in the risk of death from COVID-19, and high-risk individuals should be identified using approaches that can address the abovementioned three problems. Although COVID-19 involves mostly mild infections among the majority of the general population, the risk of death among young adults is higher than that of seasonal influenza, and elderly with underlying comorbidities require additional care.

Citing Articles

Role of Trust, Risk Perception, and Perceived Benefit in COVID-19 Vaccination Intention of the Public.

Man S, Wen H, Zhao L, So B Healthcare (Basel). 2023; 11(18).

PMID: 37761786 PMC: 10530888. DOI: 10.3390/healthcare11182589.


Use of data mining approaches to explore the association between type 2 diabetes mellitus with SARS-CoV-2.

Ghazizadeh H, Shakour N, Ghoflchi S, Mansoori A, Saberi-Karimiam M, Rashidmayvan M BMC Pulm Med. 2023; 23(1):203.

PMID: 37308948 PMC: 10258488. DOI: 10.1186/s12890-023-02495-4.


Recent advances in sensitive surface-enhanced Raman scattering-based lateral flow assay platforms for point-of-care diagnostics of infectious diseases.

Kim K, Kashefi-Kheyrabadi L, Joung Y, Kim K, Dang H, Chavan S Sens Actuators B Chem. 2022; 329:129214.

PMID: 36568647 PMC: 9759493. DOI: 10.1016/j.snb.2020.129214.


Mutation and SARS-CoV-2 strain competition under vaccination in a modified SIR model.

Ahumada M, Ledesma-Araujo A, Gordillo L, Marin J Chaos Solitons Fractals. 2022; 166:112964.

PMID: 36474823 PMC: 9715496. DOI: 10.1016/j.chaos.2022.112964.


Perceived risk of COVID-19 diagnosis and stigma among Nigerians.

Esiaka D, Nwakasi C, Mahmoud K, Philip A Sci Afr. 2022; 18:e01411.

PMID: 36313264 PMC: 9596177. DOI: 10.1016/j.sciaf.2022.e01411.


References
1.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View

2.
Kelly H, Cowling B . Case fatality: rate, ratio, or risk?. Epidemiology. 2013; 24(4):622-3. DOI: 10.1097/EDE.0b013e318296c2b6. View

3.
Ghani A, Donnelly C, Cox D, Griffin J, Fraser C, Lam T . Methods for estimating the case fatality ratio for a novel, emerging infectious disease. Am J Epidemiol. 2005; 162(5):479-86. PMC: 7109816. DOI: 10.1093/aje/kwi230. View

4.
Linton N, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov A, Jung S . Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. J Clin Med. 2020; 9(2). PMC: 7074197. DOI: 10.3390/jcm9020538. View

5.
de Sousa R, Reusken C, Koopmans M . MERS coronavirus: data gaps for laboratory preparedness. J Clin Virol. 2013; 59(1):4-11. PMC: 7108266. DOI: 10.1016/j.jcv.2013.10.030. View